[1]
Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA. 2010 Jul 28:304(4):452-60. doi: 10.1001/jama.2010.1014. Epub
[PubMed PMID: 20664046]
Level 1 (high-level) evidence
[2]
Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. American journal of respiratory and critical care medicine. 2000 Jan:161(1):309-29
[PubMed PMID: 10619836]
[3]
Bonner LT, Peskind ER. Pharmacologic treatments of dementia. The Medical clinics of North America. 2002 May:86(3):657-74
[PubMed PMID: 12171061]
[5]
Nilsson E. Physostigmine treatment in various drug-induced intoxications. Annals of clinical research. 1982 Aug:14(4):165-72
[PubMed PMID: 7168546]
[6]
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016 Jul 26:87(4):419-25. doi: 10.1212/WNL.0000000000002790. Epub 2016 Jun 29
[PubMed PMID: 27358333]
Level 3 (low-level) evidence
[7]
Wess J. Molecular biology of muscarinic acetylcholine receptors. Critical reviews in neurobiology. 1996:10(1):69-99
[PubMed PMID: 8853955]
[8]
Nathanson NM, Molecular properties of the muscarinic acetylcholine receptor. Annual review of neuroscience. 1987;
[PubMed PMID: 2436543]
[9]
Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nature reviews. Drug discovery. 2007 Sep:6(9):721-33
[PubMed PMID: 17762886]
[10]
Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Current neuropharmacology. 2013 May:11(3):315-35. doi: 10.2174/1570159X11311030006. Epub
[PubMed PMID: 24179466]
[11]
Stavrakis S, Yu X, Patterson E, Huang S, Hamlett SR, Chalmers L, Pappy R, Cunningham MW, Morshed SA, Davies TF, Lazzara R, Kem DC. Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. Journal of the American College of Cardiology. 2009 Sep 29:54(14):1309-16. doi: 10.1016/j.jacc.2009.07.015. Epub
[PubMed PMID: 19778674]
[13]
King AM, Aaron CK. Organophosphate and carbamate poisoning. Emergency medicine clinics of North America. 2015 Feb:33(1):133-51. doi: 10.1016/j.emc.2014.09.010. Epub 2014 Nov 15
[PubMed PMID: 25455666]
[14]
Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet (London, England). 2008 Feb 16:371(9612):597-607
[PubMed PMID: 17706760]
[15]
Newmark J. Therapy for acute nerve agent poisoning: An update. Neurology. Clinical practice. 2019 Aug:9(4):337-342. doi: 10.1212/CPJ.0000000000000641. Epub
[PubMed PMID: 31583189]
[17]
Holstege CP, Kirk M, Sidell FR. Chemical warfare. Nerve agent poisoning. Critical care clinics. 1997 Oct:13(4):923-42
[PubMed PMID: 9330846]